NEW YORK, Feb 09, 2015 (BUSINESS WIRE) -- Medidata MDSO, -1.69% the leading global provider of cloud-based solutions for clinical research in life sciences, today announced a strategic collaboration with Garmin International Inc., a unit of Garmin Ltd. By integrating Garmin’s vívofit activity tracker with the Medidata Clinical Cloud®, Medidata is enabling its life sciences customers to make use of mobile health (mHealth) devices with the potential to enhance patient engagement, data quality and operational efficiencies in clinical trials.
Designed to be worn on a person’s wrist 24/7, Garmin’s vívofit measures steps taken, distance, calories burned and hours slept. The water-resistant device-which displays fitness data through its always-on LCD display-is being used by Medidata to capture patient data in clinical trials. The company selected the vívofit because of the ease of use provided by its year-long battery life, which can improve the convenience and speed associated with capturing direct-from-patient data and, as such, has the potential to increase compliance among study participants in a clinical trial setting.
“We’re thrilled to be working with Garmin, a company that shares our passion for innovation and our commitment to enhancing people’s health and well being,” said Glen de Vries, Medidata’s president. “Integrating the vívofit with the Medidata platform is part of our ongoing efforts to unify mHealth devices with cloud-based technologies in a clinical trial setting. We believe these efforts will result in better data, enhanced patient experiences and more efficient trials.”
Medidata has built cloud-based infrastructure that enables life sciences companies to explore the use of mHealth technologies in clinical research. This infrastructure gathers data from devices worn by patients and integrates it with other traditional clinical data, including labs, vital signs, medical history and adverse events. In doing so, the infrastructure provides life sciences companies with the ability to conduct sophisticated analysis on trial performance. Medidata is currently working with top life sciences organizations to explore the feasibility of using the vívofit in clinical trials. The data is pulled from the Garmin activity tracker in 15-minute increments and then analyzed to evaluate its connection with traditional clinical measures and determine whether it can provide better insight into patient health status or response to therapy.
“At Garmin, our mission is to develop innovative technology that promotes healthy and active lifestyles,” said Allison Swelin, Strategic Partnership Development Manager at Garmin International. “We’re excited to see Medidata use the vívofit in their pursuit to help the global life sciences industry find better, easier ways to collect data directly from patients.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.